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Background and aim: ABPA is radiologically classified on the presence or absence of central
bronchiectasis (CB) as ABPA-CB and serologic ABPA (ABPA-S) respectively. Few studies have
described the follow-up of patients with ABPA-S. The aim of this retrospective study was to
describe the outcomes of ABPA-S.
Methods: Patients were diagnosed as ABPA-S if they met all the following criteria: asthma,
immediate cutaneous hyperreactivity to Aspergillus fumigatus antigen, total IgE levels
>1000 IU/mL, A. fumigatus specific IgE levels >0.35 kUA/L and normal HRCT of the chest. They
were treated with glucocorticoids and followed up with history, physical examination, chest
radiograph and total IgE levels every 6 weeks to 3 months. In addition, an annual spirometry
and a biennial HRCT chest were performed in all patients.
Results: Of the 55 patients with ABPA-S, 41 (17 men, 24 women; mean age, 38.3 years) con-
sented for performance of repeat HRCT scans. The median duration of asthma prior to diag-
nosis of ABPA was six years. The duration of follow-up ranged from 24 to 77 months with the
mean (SD) follow-up duration being 43.7 (10.1) months. There was improvement in FEV1 but
not the FVC values during the follow-up period (p values Z 0.001 and 0.5 for FEV1 and FVC
respectively). There was no development of CB in any patient. Sixteen patients had a relapse
during the follow-up period, and six patients were classified as glucocorticoid-dependent
ABPA.
Conclusions: Although relapses are frequently seen, the long-term outcome of ABPA-S is good
with no patient developing CB.
ª 2012 Elsevier Ltd. All rights reserved.72 2756825; fax: þ91 172 2748215.
.com, agarwal.ritesh@pgimer.edu.in (R. Agarwal).
2 Elsevier Ltd. All rights reserved.
ABPA-S : Long-term outcomes 943Introduction fumigatus specific IgE levels >0.35 kUA/L; and, (e) normal
HRCT of the chest AND any of the following criteria: (a)Allergic bronchopulmonary aspergillosis (ABPA) is a pulmo-
nary disorder caused by complex immunological reactions
to Aspergillus fumigatus that complicates the course of
asthma and cystic fibrosis.1,2 The prevalence of ABPA in
asthma varies from 2 to 32% in special clinics,3 whereas the
prevalence in cystic fibrosis ranges from 2 to 15%.4 The
condition generally presents with poorly controlled asthma,
hemoptysis, fever and weight loss.5 The Rosenberg-
Patterson criteria are most often used for diagnosis,6,7
however there is no clear consensus on the number of
criteria needed for diagnosis.8 High-resolution computed
tomography (HRCT) of the chest is the imaging modality of
choice for the diagnosis of ABPA.9 ABPA can be classified on
HRCT chest as serologic ABPA (ABPA-S), ABPA with central
bronchiectasis (ABPA-CB) and ABPA with central bronchi-
ectasis and high-attenuation mucus (ABPA-CB-HAM).10
While central bronchiectasis (CB) is considered to be
a characteristic feature of ABPA, it is not essential for
diagnosis, and CB is considered a late manifestation of the
disease.11
Patients with ABPA who otherwise fulfill all diagnostic
criteria but lack demonstrable abnormalities on CT chest
are labeled as ABPA-S.7,12e14 ABPA-S is generally believed to
be the earliest stage of ABPA with lesser degree of immu-
nological activity and a milder clinical course.12 Long-term
oral glucocorticoid therapy is often required to prevent
progression of lung damage in ABPA.15 Few studies have
described the long-term outcomes of patients with ABPA-
S.7,12e14 Moreover, no study has performed HRCT chest
during follow-up to document the development of CB in
these patients. It is essential to monitor the radiological
changes in this group of patients so as to determine the
effectiveness of therapy or the need for additional therapy.
ABPA is a common problem encountered in our asthma
clinic, and we have reported the clinical features and
outcomes of more than 200 patients with ABPA.10,16e19 In
this study, using the same dataset we describe the long-
term outcomes of patients with ABPA-S.Material and methods
The current study is a retrospective analysis, and includes
patients of ABPA-S diagnosed between January 2004 and
December 2008 and followed till December 2010. The
baseline characteristics of these patients have already
been previously reported.10,16e18 This study describes the
follow-up of patients with ABPA-S. A written informed
consent was taken from all patients and the study was
approved by the Institute Ethics Committee.
We screen all patients of asthma in our Chest clinic with
an Aspergillus skin test. Patients demonstrating immediate
hypersensitivity in Aspergillus skin test are further inves-
tigated for ABPA with total and A. fumigatus specific IgE
levels, Aspergillus precipitins, eosinophil count and HRCT
of the chest. Patients are diagnosed as ABPA-S if they
meet all the following criteria: (a) diagnosis of bronchial
asthma (b) immediate cutaneous hyperreactivity to A.
fumigatus antigen; (c) total IgE levels >1000 IU/mL; (d) A.presence of serum precipitins against A. fumigatus; (b)
fleeting opacities on the chest radiograph and, (c) total
eosinophil count >1000 cells/mL.19
Aspergillus skin test
Was performed by injecting 0.2 mL of the A. fumigatus
antigen (100 PNU/mL) intradermally in the forearm.20
0.2 mL of phosphate buffer saline is used as negative
control. The injection site is examined every 15 min for 1 h,
and then after six to 8 h. The reactions are classified as type
I if wheal and erythema developed within a minute,
reached a maximum after 10e20 min and resolved within
1e2 h. Type III reactions are defined by the presence of any
amount of subcutaneous edema after 6 h.
Levels of serum IgE (total) and IgE (for A.
fumigatus)
Were assayed with commercially available kits using the
quantitative enzyme-linked immunosorbent assay (Deme-
ditec diagnostics GmbH, Kiel, Germany) and the fluorescent
enzyme immunoassay (UniCap Systems; Phadia, Stockholm,
Sweden) as per the manufacturer’s instructions.
High-resolution CT of the chest
Was performed on a 16-row, multiple detector, CT scanner
(LightSpeed Plus; GE Medical Systems; Slough, UK) with
a 512 matrix size. The scans were obtained with a scan time
of 3 s in the supine position at full end-inspiration from lung
apex to base. The image acquisition was contiguous and the
images (1.25 mm at 10-mm intervals) were reconstructed
using the high-spatial-frequency algorithm. The HRCT chest
was reported by a radiologist (MG) as well as independently
interpreted by a clinician (RA) unblinded to the patient
identity or clinical presentation.
A. fumigatus precipitins
Were detected by the Ouchterlony’s gel diffusion tech-
niques according to the method of Longbottom and Pepys.21
Spirometry
Was performed using commercial dry rolling seal spirometer
(Spiro RS-232; P.K. Morgan Limited; Kent, UK) and the
forced expiratory volume in the first second (FEV1) and
forced vital capacity (FVC) measurements were recorded.
Patients were classified as mild, moderate and severe
obstruction as per the standardized practice in our
laboratory.22
Total eosinophil count
Was performed by manually counting 100 cells on the
peripheral blood film after determining the total white cell
count on an automated blood cell analyzer.
Table 1 Baseline characteristics of patients with ABPA-S
(n Z 41).
Demographic details
Age (years), mean (SD) 38.3 (13.4)
Male Gender, No. (%) 17 (41.5)
History
Duration of Asthma (years),
median (IQR)
6 (4e13)
Hemoptysis, No. (%) 8 (19.5)
Expectoration of brownish
black mucous plugs,
No. (%)
15 (36.6)
History of anti-tuberculous
therapy, No. (%)
7 (17.1)
Spirometry, No. (%)
Normal 21 (51.2)
Mild obstruction 11 (26.8)
Moderate obstruction 8 (19.5)
Severe obstruction 1 (2.4)
Immunological findings
Aspergillus skin test, No. (%)
Type I 41 (100)
Type III 35 (85.4)
Eosinophil count (cells/mL),
median (IQR)
750 (250e981)
Eosinophil count >1000
cells/mL, No. (%)
9 (22)
Aspergillus precipitins,
No. (%)
37 (90.2)
Total IgE levels (IU/mL),
median (IQR)
4100 (2965e7567)
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The patients were treated with glucocorticoids with the
following regimen: prednisolone 0.75 mg/kg/day for six
weeks, 0.5 mg/kg/day for six weeks; then tapered by 5 mg
every six weeks to continue for a total duration of at least
six to twelve months and followed up with history and
physical examination, and total IgE levels every six weeks
to three months.4 In addition, chest radiograph was per-
formed in patients who had clinical worsening. Patients
were classified to be in remission, if the IgE levels declined
by 25e35% and there was clinical improvement after
three months of glucocorticoids. Once the patient was in
remission IgE levels were performed every three to six
months or during any worsening of symptoms. During
remission, the patients were treated with a combination of
formoterol/budesonide at a dose of 24/1600 mg per day
using a transparent small volume valved spacer (Zerostat
VT, Cipla, India). For any worsening of asthma symptoms,
the patients were advised to take levosalbutamol 50 mg as
needed. A doubling of baseline IgE levels with clinicor-
adiological worsening was defined as a relapse. In case of
relapses, the patient was initiated on glucocorticoids
(0.5 mg/kg/day prednisolone for four weeks, 0.25 mg/kg/
day for four weeks, then tapered by 5 mg every four weeks)
and itraconazole 200 mg twice daily for four months. If the
patient required oral prednisolone for recurrent relapses of
ABPA, then the patient was said to have glucocorticoid-
dependent ABPA. Patients with ABPA-S underwent
spirometry and HRCT chest at baseline with spirometry
repeated annually and HRCT chest performed every two
years on follow-up.A. fumigatus specific IgE
levels (kUA/L), median (IQR)
3.5 (1.3e9.5)Statistical analysis
Data are presented as mean (SD), median (IQR) or number
(percentage). Statistical significance was assumed at a p
value of less than 0.05. Differences between continuous
variables were analyzed using ManneWhitney U test while
the differences between categorical variables were
assessed using chi-square test. The repeated measures of
FEV1 and FVC were analyzed using Friedman test.Results
During the study period, ABPA-S was diagnosed in 55
patients, and CT could be performed in 41 patients (7
patients lost during follow-up, 7 refused consent for
performance of CT scan). There were 17 men and 24 women
with a mean (SD) age of 38.3 (13.4) years. The median
duration of asthma prior to diagnosis of ABPA was six years
and seven patients had inappropriately received anti-
tuberculous therapy for complaints of hemoptysis without
any evidence of tuberculosis (Table 1). Spirometry was
normal in 21 (51.2%) patients while the remaining had
obstructive defect. The immunological findings including
absolute eosinophil counts, IgE levels (total), A. fumigatus
specific IgE levels and Aspergillus precipitins are shown in
Table 1. Chest radiograph records did not demonstrate
fleeting pulmonary opacities in any patient.After treatment with glucocorticoids, all the patients
went into remission at three months. However, 16
patients had a relapse during the follow-up period. The
majority of these patients relapsed once (nZ 10) while five
had two relapses and one patient three relapses. All
relapses were clinical and immunological while one patient
also had radiologic relapse. All patients were restarted on
therapy with prednisolone and itraconazole. Of the 16
patients who relapsed, all went into remission at three
months; however therapy could be stopped completely only
in 10 patients while the remaining patients were classified
as glucocorticoid-dependent ABPA. There was no statisti-
cally significant difference between any demographic
characteristics, spirometry and immunological findings in
patients with and without relapse (Table 2).
The duration of follow-up of these 41 patients ranged
from 24 to 77 months (3.7 patient years) with the mean (SD)
follow-up being 43.7 (10.1) months. The annual lung func-
tion measurements of these patients are shown in
Fig. 1.There was improvement in FEV1 but not the FVC
values during the follow-up period (p values Z 0.001 and
0.5 for FEV1 and FVC respectively). HRCT chest was per-
formed every two years in all these patients. None of the
patient developed any evidence of bronchiectasis on
HRCT chest during the follow-up period.
Table 2 Demographic, spirometric and immunological findings in patients with and without relapse.
Relapses absent (n Z 25) Relapses present (n Z 16) P value
Demographic characteristics
Age (years), mean (SD) 35.6 (11.9) 42.5 (14.7) 0.12
Male Gender, No. (%) 9 (36) 8 (50) 0.38
History of smoking, No. (%) 3 (12) 2 (12.5) 0.96
Duration of Asthma (years),
median (IQR)
5 (4.5e13) 7 (3.3e14.3) 0.86
Obstructive defect on
spirometry, No. (%)
11 (44) 9 (56.2) 0.45
Immunological findings
Type III skin reaction, No. (%) 21 (84) 14 (87.5) 0.76
Absolute eosinophil count
(cells/mL), median (IQR)
750 (250e1124) 726 (280e818) 0.50
Aspergillus precipitins, No. (%) 23 (92) 14 (87.5) 0.61
Total IgE levels (IU/mL),
median (IQR)
3850 (2768e7567) 4428 (3115e8795) 0.39
A. fumigatus specific IgE levels
(kUA/L), median (IQR)
2.6 (1.3e8.8) 5.2 (1.5e13.3) 0.38
ABPA-S : Long-term outcomes 945The treatment was well tolerated although the occur-
rence of moon facies and/or weight gain (of >5%) were
observed in majority of the patients. One patient each
developedhypertensionandhyperglycemiaduring follow-up.Discussion
The results of this study suggest that patients with ABPA-S
treated with a protocol of glucocorticoids do not develop
central bronchiectasis on HRCT chest during therapy. More
than five decades into existence, ABPA is still under
recognized with almost 40% of the patients misdiagnosed as
pulmonary tuberculosis.10 Even in this study, patients with
normal chest radiograph and hemoptysis were empirically
started on anti-tuberculous therapy prior to referral. HRCT
chest findings correlate with immunological severity in
ABPA, and we had earlier reported that hyperattenuating
mucus on HRCT chest was the most consistent marker of
immunological severity.12 Moreover, the CT findings of high-
attenuation mucus and bronchiectasis at diagnosis are
independent predictors of relapses in ABPA.10,17,18 Thus,Figure 1 Box and whisker plot depicting forced expiratory volum
at baseline and during follow-up (Box plots represent the 25th and
median and T-bars the 10th and 90th percentiles; circles represenABPA needs to be recognized before the development of
bronchiectasis, and the aim of current therapy is to control
the immunological activity not only to prevent relapses and
manage asthma but also to prevent bronchiectasis.8
ABPA-S was first described by Patterson et al. in 1986
where they reported 13 patients with all serological char-
acteristics of ABPA but not CB although 54% of patients with
ABPA-S in this study were classified as glucocorticoid-
dependent ABPA.7 Greenberger et al. described immuno-
logical findings in 28 patients with ABPA-S. Eleven of these
28 patients were followed up for 63 patient years. Four of
these 11 patients developed pulmonary infiltrates during
exacerbation and one patient demonstrated apical fibrosis.
A repeat HRCT of the chest or bronchography was not
carried out in any patient.12 Kumar et al. in two different
studies described the outcome of 17 patients with ABPA-
S.13,14 Although these studies documented lesser frequency
of exacerbations, neither of the study had performed HRCT
chest scans on follow-up to document the occurrence of
bronchiectasis. The results of the aforementioned studies
are limited not only by the lack of HRCT scans on follow-up
but also the small sample size (Table 3). Most of thesee in the first second and forced vital capacity values in patients
75th percentiles, with the internal horizontal line showing the
t outliers).
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946 R. Agarwal et al.studies have followed the patients using chest radiographs
and it is well recognized that HRCT chest can detect
bronchiectasis that is not apparent on the chest
radiograph.23
The differentiation of patients with ABPA-S from patients
with A. fumigatus associated asthma (AFAA) is problematic
as many findings of ABPA-S like Aspergillus skin test posi-
tivity, raised IgE levels both total and A. fumigatus specific
can be encountered in AFAA although the magnitude of rise
in immunological markers is far greater in ABPA-S compared
to AFAA.24 The differentiation is however important
between these two entities because patients with ABPA-S
require treatment with glucocorticoids to control the
immune activity while those with AFAA do not. The median
IgE levels (both total and A. fumigatus specific) and eosin-
ophil count were significantly raised in this study group,
which are unlikely to be encountered in patients with AFAA.
Similarly, the prevalence of Aspergillus precipitins in ABPA-S
was very high, which is again unlikely to be seen in AFAA.
Several investigations suggest that ABPA-S probably
represents the earliest stage of the disease with less severe
immunologic findings,10,12e14 and lesser propensity for
relapses.10,17,18 However, this does not imply that the
disease is immunologically inactive as almost 15% in the
current study and 27e54% patients in previous studies have
been shown to have glucocorticoid-dependent disease.7,12
Further, almost 39% of these patients experienced
relapses in our study suggesting an immunologically active
disease with need for close and long-term follow-up.
Whether treatment of ABPA-S with glucocorticoids
prevents the development of bronchiectasis in these patients
is not certain because of the lack of a control group. It may
well be argued that this subgroup of patients could be
genetically predisposed not to develop bronchiectasis.
However, we have shown that patients with ABPA-S when
treated with inhaled corticosteroids only, develop immuno-
logical worsening manifested by increasing IgE levels, which
ultimately respond to oral glucocorticoids.19 Moreover,
progression from ABPA-S to ABPA-CB stage has been docu-
mented on long-term follow-up of a patient inadequately
treated for the disease.25 Hence, it is seems likely that early
diagnosis and treatment can prevent progression of ABPA-S to
ABPA-CB. One can also questionwhether the interventionwas
remarkably aggressive for an entity that did not necessarily
involveany structural lungdamagewithhalf thepatients even
having a normal spirometry. However, this aggressive
approach may be justified by the lack of progression to
bronchiectasis in this cohort with minimal adverse events
from therapy. Not only bronchiectasis is an indicator of
permanent lung damage, it has also been shown that the
occurrence of bronchiectasis is a poor prognostic marker in
this disease with propensity for recurrent relapses.10,17,18
Finally, the study is not without limitations. The major
limitation is the retrospective nature of the study, which
limits the analysis to the available data, and it is possible
that certain important information has been missed. The
other limitation is the observational nature of the study.
Ideally, a randomized controlled trial or a caseecontrol
study comparing oral steroids with placebo is the ideal
approach. However, the results of this study do reinforce
the need for active screening of all patients of asthma with
Aspergillus skin test irrespective of the severity or control
ABPA-S : Long-term outcomes 947as half the patients in the current study had normal
spirometry at diagnosis.
Conclusions
The result of this study reinforces the need for routine
screening of asthmatics to diagnose ABPA before the onset of
bronchiectasis as early diagnosis and treatment of ABPA-S can
prevent the disease from progressing to the stage of central
bronchiectasis. Despite being an early stage of the disease,
ABPA-S is immunologically active with tendency for relapses
and development of glucocorticoid-dependent disease, and
hence underscores the need for close monitoring.
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